Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Just For You
Abbott Stock Crash: Rebound Could Be Coming FastAuthor: Thomas Hughes. Posted: 4/17/2026. 
Key Points
- Abbott Laboratories' stock price sell-off is overblown and unrealistic, providing an attractive opportunity in Q2.
- Institutions and analysts are accumulating this stock, indicating solid double-digit upside potential.
- Acquisitional woe hinders price action in April, but sets the market up for positive surprises and rebound later this year.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
Abbott Laboratories' (NYSE: ABT) share price fell roughly 45% from peak to trough, bottoming in early Q2 2026 after reaching deeply oversold levels.
The "Sucker's Bet" Most New Options Traders Fall For
Most people who try options lose money the same way.
They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter.
Normally $29.97. Free today. Download your copy now.
There are valid reasons for the sell-off, but its magnitude is excessive when viewed against the underlying fundamentals. Mixed results at the end of 2025, cautious guidance and a debated acquisition plan left investors uncomfortable. The relevant question is who is doing the selling and who is buying — and the data isn’t particularly surprising. ABT Stock Is Well-Supported by Sell-Side InterestsMarketBeat's data shows solid support for Abbott among sell-side analysts. Of the 21 analysts tracked, the consensus leans to a Moderate Buy, with an 81% Buy-side bias and a stable price-target trend. Some price-target reductions followed the Q4 results, but they were largely in line with consensus and sentiment has trended more bullish since. In early April, Barclays analyst Matt Miksic raised his target to $144, reaffirming an Overweight rating. That level is roughly 7.5% above the consensus target and about 40% above critical support levels. Institutional investors are also constructive, owning more than 75% of the float and having accumulated for seven consecutive months. Early Q2 activity shows some distribution, but that can change quickly. Data from 2026 shows bullish activity ramping in Q1, hitting a multiyear high even as the share price declined. If institutions and other buyers take advantage of the post–fiscal Q1 weakness, Abbott’s price floor is likely in the mid‑$90s. Abbott Laboratories Market Hits Bottom in Q2The ABT stock price pulled back sharply after the Q1 release and could test lower, but early action suggests a market bottom. The stock gapped down at the open and then traded in a tight range near key support levels, signaling steady activity at these lows. Volume spiked alongside the price dip, reaching long-term intraday highs — a pattern often consistent with accumulation. 
The timing of a rebound may be sooner than some expect. Technical indicators show deeply oversold readings on the stochastic oscillator while the MACD is diverging, suggesting bears are losing momentum and bulls may be stepping in. A visible catalyst could accelerate the move higher — one candidate is clearer progress integrating Exact Sciences, the maker of Cologuard and Abbott’s entry into the higher-growth oncology diagnostics market. The main risk is that the stock remains near current lows for several quarters. Even that scenario could offer buying opportunities: investors can use nearby support levels as entry points to build positions over time. Abbott Laboratories Falls Despite Strong QuarterAbbott did not report a bad quarter, but management acknowledged a near-term impact from the acquisition. Still, revenue grew 7.8% year over year, with comparable growth of 3.7%. Foreign exchange provided a roughly 400 basis-point tailwind, with U.S. sales up about 2.5% and international sales rising more than 4.5%. By segment, Nutrition was the weakest, down 7.7% due to volume and pricing pressure, while other segments posted gains. Diagnostics grew 2.5% but is expected to accelerate with Exact Sciences in the portfolio. Established Pharmaceuticals and Medical Devices led the way, up 9% and 8.1%, respectively, underscoring Abbott’s diversification. Margins were a disappointment relative to the top-line strength, which helps explain some of the selling. Adjusted earnings came in essentially as expected despite the 145 basis points of top-line strength. The takeaway: earnings are sufficient to support Abbott’s strong balance sheet and robust capital-return program, and guidance is constructive. Management Guides In Line With ExpectationsLooking ahead, management expects sequential revenue acceleration and margin recovery, forecasting 7% comparable growth at the midpoint and $5.48 in annual adjusted EPS — roughly a penny above consensus. Given Abbott’s track record of successful acquisitions and integrations, the company is well positioned to execute and potentially exceed expectations. In the near term, Abbott’s dividend and share-buyback program should remain in place. The dividend yields a historically high 2.5% at mid‑April lows and comes from a company with an impressive pedigree: ABT is both a Dividend Aristocrat and a Dividend King, having raised its payout for over 50 consecutive years. |
Post a Comment
Post a Comment